InvestorsHub Logo
Followers 1
Posts 150
Boards Moderated 0
Alias Born 03/22/2009

Re: Whalatane post# 73394

Friday, 02/26/2016 8:47:50 PM

Friday, February 26, 2016 8:47:50 PM

Post# of 426528
valuation of early stage biotechs is a lot of art.

It's tough enough to get the earnings model correct but the discount rate is equally important. Since you previously posted that Reduce-it would be successful at the final look with 100% certainty then perhaps a 25% discount rate is appropriate. If anything, it seems low to me but it's really anyone's guess.

Btw. take a look at Sun Trust's cash flow projections. He is not projecting more financings.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News